Home / Healthcare/ FDA clears Novo Nordisk’s diabetes drug to reduce cardiovascular risk

FDA clears Novo Nordisk’s diabetes drug to reduce cardiovascular risk


Comments / {{hitsCtrl.values.hits}} Views / Monday, 28 August 2017 00:09


Reuters: Novo Nordisk said on Friday the US Food and Drug Administration (FDA) approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke.

1Novo Nordisk logo is seen in Bagsvaerd outside of Copenhagen, Denmark – REUTERS

This is the first time the FDA has cleared a diabetes drug for reducing risks of heart attack, stroke and cardiovascular deaths in patients with type 2 diabetes, the company said in a statement.

In December, the FDA had approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc’s drug, Jardiance, to reduce the risk of cardiovascular death in patients with type 2 diabetes.

Novo Nordisk’s Victoza, which was approved in 2010 to treat patients with type 2 diabetes, brought in 11.5 billion Danish crown ($1.84 billion) in the first six months of 2017.

Type 2 diabetes, closely linked to obesity, accounts for more than 90% of all diabetes cases, the company said.

Victoza’s expanded label follows a successful trial that showed the drug significantly reduced the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke by 13% when compared to a placebo.

Heart disease is the leading cause of death in the United States, killing about 610,000 people every year, according to the Centers for Disease Control and Prevention.

Adults with type 2 diabetes are up to four times more likely to develop cardiovascular disease, the company said.


Share This Article


COMMENTS

Today's Columnists

Walking an adaptable path to your cloud vision

Tuesday, 16 January 2018

While most companies have a vision of their cloud future – where everything in IT is simple, flexible, elastic making it easy to innovate, be swift to market and delight customers– fewhave a clear view of how to get there.This isbecause they are


International Financial Reporting Standard for Insurance Contracts (IFRS 17) in Sri Lankan insuran

Tuesday, 16 January 2018

Insurance accounting has never been easier for accountants due to the complicated nature of insurance contracts when assessing the liability arising from insurance contracts. This is where actuarial skills and expertise are required in order to calcu


In praise of President Sirisena

Tuesday, 16 January 2018

“Being in a minority, even in a minority of one, did not make you mad. There was truth and there was untruth, and if you clung to the truth even against the whole world, you were not mad.” –George Orwell, 1984


Five Ps – President, Parliament, Politics, Performance and People

Tuesday, 16 January 2018

As we all know, President Maithripala Sirisena has sought the opinion of the Supreme Court that whether, he, as the person elected on 9 January 2015, has any impediment to continue in the office of President for a period of six years. In terms of the


Columnists More